HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma
Status:
Not yet recruiting
Trial end date:
2024-12-15
Target enrollment:
Participant gender:
Summary
This study is conducted in patients with advanced hepatocellular carcinoma (HCC). This study
includes three arms: A, B, and C. Arm A will receive HLX07 combination therapy with HLX10 and
HLX04 as first line treatment. Arm B will receive HLX07 combination therapy with lenvatinib
as second line treatment. Arm C will receive HLX07 monotherapy as third-line or above
treatment. All of eligible patients will receive study drug treatment until loss of clinical
benefit, unacceptable toxicity, death, withdrawal of informed consent (whichever occurs
first, HLX10 treatment up to 2 years).